Comparative Risk of Incident Inflammatory Bowel Disease in Psoriatic Arthritis Treated With IL-17 Inhibitors Versus TNF Inhibitors: A Propensity-Matched Cohort Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1677; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Cohort A received an IL-17 inhibitor, including secukinumab, ixekizumab, bimekizumab, or brodalumab, while Cohort B received a TNF inhibitor, including adalimumab, infliximab, certolizumab pegol, or golimumab...Propensity matching included demographics, age, sex, race, ethnicity, and clinical covariates including diabetes mellitus, overweight/obesity, celiac disease, tobacco use, NSAID use, antimicrobial exposure, glucocorticoid use, and methotrexate use... In this large, propensity-matched cohort of adults with PsA, IL-17 inhibitor use was associated with a significantly lower observed incidence of IBD compared with TNF inhibitor use at 1, 3, and 5 years. These findings may help inform biologic selection and counseling in PsA patients without known IBD, suggesting that IL-17 inhibitors should not be avoided solely because of concern for incident IBD. However, given known safety warnings and the observational design, clinicians should continue to screen for..."
Celiac Disease • Crohn's disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Nicotine Addiction • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL17A
|
|
Bsher Almaalouli1; Javairia Jamil1; Farah Haneyah1; Adnan Saydawi2; Sameh Madanieh3; Obada Abusurrah1; Hesham Nasser4
|